Clinical Trials Browser

enzalutamide × Other solid neoplasm × 90 days × Clear all

NCT06576037 2026-04-16

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Phase 1 Recruiting

Other solid neoplasm

Solid Tumor